SOHO Italy 1st School of Acute Leukemia

 

SOHO Italy 1st School of Acute Leukemia
Avatar

Optimizing FLT3i Use in FLT3+ AML in 2021: What Are the Current and Future Therapeutics?

By SOHO Italy 1st School of Acute Leukemia FEATURING Naval Daver
By SOHO Italy 1st School of Acute Leukemia FEATURING Naval Daver
0 views
May 4, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Videos
13:35
SOHO Italy 1st School of Acute Leukemia

The Road to AML: A Clinical and Biological Overview

Feat. S. Galimberti
07:52
SOHO Italy 1st School of Acute Leukemia

AML Molecular Pathogenesis & Approach to Therapeutic Targets

Feat. S. Galimberti
10:49
SOHO Italy 1st School of Acute Leukemia

FLT3m AML: Midostaurin + Chemo, Sorafenib Maintenance After Allo-HSC…

Feat. G. Martinelli
25:10
SOHO Italy 1st School of Acute Leukemia

AML in 2021: MD Anderson Perspective on Progress in Research and The…

Feat. H. Kantarjian
20:05
SOHO Italy 1st School of Acute Leukemia

Optimizing FLT3i Use in FLT3+ AML in 2021: What Are the Current and …

Feat. N. Daver
15:43
SOHO Italy 1st School of Acute Leukemia

2021 AML Drugs in EU: Microenvironment & Parasite Relations, Pot…

Feat. G. Martinelli
16:03
SOHO Italy 1st School of Acute Leukemia

2021 Updates on the Role of Maintenance in AML: Stem Cell Modeling, …

Feat. M. Gottardi
15:53
SOHO Italy 1st School of Acute Leukemia

Role of SCT in AML: Choice of Donor, HSCT in Active Disease, Older P…

Feat. A. Olivieri
14:48
SOHO Italy 1st School of Acute Leukemia

Environment-Mediated Drug Resistance in AML: Is Targeting CAMDR a Ne…

Feat. C. Cerchione
09:40
SOHO Italy 1st School of Acute Leukemia

Role of Single Agent IDHi in AML: Effects on Hematopoiesis, Ena/Ivo …

Feat. M. Paola Martelli
05:02
SOHO Italy 1st School of Acute Leukemia

IDH1/2 Inhibitor Combinations for AML: Ivo/Ena+Aza for Newly Diagnos…

Feat. M. Paola Martelli
14:25
SOHO Italy 1st School of Acute Leukemia

2021 Updates on Ph+ ALL: Chemo+Dasatinib, Dasatinib vs. Imatinib in …

Feat. E. Jabbour
12:15
SOHO Italy 1st School of Acute Leukemia

Integrating IO in the Frontline ALL: Hyper-CVAD+Ponatinib, Blina+Ino…

Feat. E. Jabbour
16:56
SOHO Italy 1st School of Acute Leukemia

Novel Antibodies in AML: What Is the Role of Gemtuzumab Ozogamicin? …

Feat. F. Ravandi
16:41
SOHO Italy 1st School of Acute Leukemia

AML Management: Strategies to Integrate IO & Targeted Therapies

Feat. N. Daver
13:23
SOHO Italy 1st School of Acute Leukemia

CAR-T Based Approach in ALL: Humanized CAR-T, Fast-Off Rate Low-Affi…

Feat. J. Ribera
07:44
SOHO Italy 1st School of Acute Leukemia

How Do I Manage Ph-Like ALL at MD Anderson: HCVAD + Ofatumumab, Test…

Feat. M. Konopleva
05:05
SOHO Italy 1st School of Acute Leukemia

How Do I Manage ETP ALL at MD Anderson: Hyper-CVAD + Nelarabine, Hyp…

Feat. M. Konopleva
24:35
SOHO Italy 1st School of Acute Leukemia

CD19 Cells in Childhood & Adult ALL Relapsed After ASCT: Anti-CD…

Feat. A. Rambaldi
20:15
SOHO Italy 1st School of Acute Leukemia

Role of mAbs in R/R ALL: INO vs. SoC, INO for B-Cell Disease Eligibl…

Feat. F. Lanza
14:08
SOHO Italy 1st School of Acute Leukemia

2021 ALL Updates: Disease Identification Markers, INO vs. SoC in R/R…

Feat. G. Martinelli
21:41
SOHO Italy 1st School of Acute Leukemia

2021 Updates on MRD Assessment and Impact on AML: MRD Monitoring, EL…

Feat. F. Buccisano
19:42
SOHO Italy 1st School of Acute Leukemia

How I Manage ALL in 2021: Can Adult Ph+ Patients Achieve CMR With Da…

Feat. G. Martinelli
26:39
SOHO Italy 1st School of Acute Leukemia

2021 MD Anderson Updates on ALL: Treatment Comparison by Age and Dis…

Feat. H. Kantarjian